Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: all 142 studies

Page 2 of 2. Open to participants first (72), then studies with results posted, then the rest; newest registration first within each.

• The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy SubjectsCompletedNCT05702983Phase 1
• ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)Active, not recruitingNCT05630612Phase 2
• Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)Status unknownNCT05416723
• Pediatric ANCA Associated-vasculitisStatus unknownNCT05383573
• Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisCompletedNCT05197842Phase 1/2
• Effect of Tofacitinib in Treating ANCA-associated VasculitisCompletedNCT04973033Not applicable
• the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated VasculitisStatus unknownNCT04923074
• Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated VasculitisActive, not recruitingNCT04916704
• Patients With Co-occurrence of ANCA Vasculitis and Sjögren SyndromeCompletedNCT04895878
• Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated VasculitisStatus unknownNCT04737343Not applicable
• PRediction Of DIverse Glucocorticoids toxIcity OUtcomeSActive, not recruitingNCT04664465
• Hydroxychloroquine in ANCA Vasculitis EvaluationTerminatedNCT04316494Phase 4
• PRagmatic Analysis of Vitamin D in ANCA-Associated VasculitisCompletedNCT04280601Not applicable
• Rituximab and Belimumab Combination Therapy in PR3 VasculitisStatus unknownNCT03967925Phase 2
• Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisStatus unknownNCT03942887Phase 3
• Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic PolyangiitisCompletedNCT03920722Phase 3
• Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated VasculitisCompletedNCT03698071Not applicable
• Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase AntibodiesCompletedNCT03385668Phase 2
• Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal DiseaseActive, not recruitingNCT03323476Phase 3
• Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyCompletedNCT03069703Phase 2
• MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITISCompletedNCT02954705
• The ANCA Vasculitis Questionnaire (AAV-PRO©)CompletedNCT02507024
• Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated VasculitisTerminatedNCT02474888
• Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated VasculitisStatus unknownNCT02463578
• Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated VasculitisCompletedNCT02463539
• Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabCompletedNCT02433522Phase 3
• The Clinical Efficacy of DFPP in Patients With AAGNTerminatedNCT02294344Not applicable
• Low-dose Glucocorticoid Vasculitis Induction StudyStatus unknownNCT02198248Phase 4
• Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic InflammationStatus unknownNCT02180126
• Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary VasculitisStatus unknownNCT02126098
• Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)CompletedNCT02108860Phase 3
• Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)CompletedNCT01862068
• Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisCompletedNCT01731561Phase 3
• CMV Modulation of the Immune System in ANCA-associated VasculitisStatus unknownNCT01633476Phase 2
• Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - EculizumabWithdrawnNCT01275287Phase 2
• Retinoids in ANCA Small Vessel Vasculitis: Silencing AutoantigensWithdrawnNCT01275274Phase 2
• Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 3
• Abatacept in ANCA Associated VasculitisTerminatedNCT00482066Phase 2
• Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated VasculitidesCompletedNCT00430105Phase 2/3
• WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated VasculitidesStatus unknownNCT00349674Phase 3
• MMF Versus CTX in the Induction Treatment of ANCA Associated VasculitisCompletedNCT00301652Not applicable
• Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and VasculitisCompletedNCT00293072Phase 2

← Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis overview